SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+55.66%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$296M
AUM Growth
+$296M
(+33%)
Cap. Flow
+$55.4M
Cap. Flow
% of AUM
18.69%
Top 10 Holdings %
Top 10 Hldgs %
46.59%
Holding
90
New
21
Increased
29
Reduced
18
Closed
11
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$24M |
| 2 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$11.5M |
| 3 |
Krystal Biotech
KRYS
|
$9.97M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$4.81M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$4.67M |
Top Sells
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$7.2M |
| 2 |
Nuvalent
NUVL
|
$7.02M |
| 3 |
Pharvaris
PHVS
|
$5.44M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$4.11M |
| 5 |
Immatics
IMTX
|
$2.9M |
Sector Composition
| 1 | Healthcare | 99.91% |
| 2 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
1
DELISTED
Immunogen Inc
IMGN
| $26.8M | 8.29% | 1,420,000 +1,270,000 | +847% | +$24M |
|
2
Merus
MRUS
$4.98B
| $15.5M | 4.8% | 589,255 -79,529 | -12% | -$2.09M |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $14.5M | 4.47% | 252,309 +200,625 | +388% | +$11.5M |
|
4
Schrodinger
SDGR
$1.44B
| $14.3M | 4.42% | 286,169 +73,344 | +34% | +$3.66M |
|
|
5
Krystal Biotech
KRYS
$4.27B
| $14M | 4.32% | 118,941 +84,927 | +250% | +$9.97M |
|
|
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.6M | 3.89% | 198,723 +73,688 | +59% | +$4.67M |
|
7
Akero Therapeutics
AKRO
$3.74B
| $11.3M | 3.49% | 241,357 +38,796 | +19% | +$1.81M |
|
8
Oric Pharmaceuticals
ORIC
$994M
| $11.3M | 3.48% | 1,450,822 +14,877 | +1% | +$115K |
|
|
9
MoonLake Immunotherapeutics
MLTX
$3.54B
| $10.2M | 3.16% | 200,000 +94,250 | +89% | +$4.81M |
|
10
Biogen
BIIB
$19.4B
| $7.65M | 2.37% | 26,854 +15,543 | +137% | +$4.43M |
|
11
89bio
ETNB
$1.34B
| $7.51M | 2.32% | 396,497 -41,718 | -10% | -$791K |
|
12
Cogent Biosciences
COGT
$1.69B
| $7.34M | 2.27% | 620,000 +40,736 | +7% | +$482K |
|
13
United Therapeutics
UTHR
$13.8B
| $6.63M | 2.05% | 30,029 +11,451 | +62% | +$2.53M |
|
14
MacroGenics
MGNX
$112M
| $6.5M | 2.01% | 1,215,675 -146,134 | -11% | -$782K |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $6.48M | 2.01% | 720,508 -3,036 | -0.4% | -$27.3K |
|
16
Veracyte
VCYT
$2.39B
| $5.84M | 1.81% | 229,451 +19,798 | +9% | +$504K |
|
17
BioCryst Pharmaceuticals
BCRX
$1.74B
| $5.36M | 1.66% | 760,904 +183,147 | +32% | +$1.29M |
|
18
Terns Pharmaceuticals
TERN
$609M
| $5.25M | 1.62% | 599,668 -68,254 | -10% | -$597K |
|
|
PSTX
19
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $5.18M | 1.6% | 2,945,948 +256,647 | +10% | +$452K |
|
|
20
Nuvalent
NUVL
$5.52B
| $4.85M | 1.5% | 115,067 -166,466 | -59% | -$7.02M |
|
21
Gilead Sciences
GILD
$140B
| $4.66M | 1.44% | 60,448 +318 | +0.5% | +$24.5K |
|
22
Vertex Pharmaceuticals
VRTX
$100B
| $4.64M | 1.43% | 13,175 -6 | -0% | -$2.11K |
|
23
TELA Bio
TELA
$70.5M
| $4.22M | 1.3% | 416,440 +362,344 | +670% | +$3.67M |
|
24
Viking Therapeutics
VKTX
$3.04B
| $4.19M | 1.3% | 258,595 -121,405 | -32% | -$1.97M |
|
25
Praxis Precision Medicines
PRAX
$958M
| $4M | 1.24% | +3,476,162 | New | +$4M |
|